Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Cancer Res. 2018 Sep 5;78(23):6594–6606. doi: 10.1158/0008-5472.CAN-18-1583

Fig. 7. Effects of CDK8 inhibition in human colon cancer models.

Fig. 7.

(A,B) qPCR analysis of the effects of Senexin B (24 hr) on the expression of (A) TIMP3 and (B) MMP9 in human colon cancer cell lines. (B) qPCR analysis of the effects of Senexin B (24 hr) on the expression of MMP9 in the indicated human colon cancer cell lines. (C-D): qPCR analysis of the effects of inducible CDK8 shRNA on TIMP3 and MMP9 expression in HCT116 cells. Cells were treated with doxycycline or vehicle control for 72 hrs, Senexin B was added for the last 24 h of treatment (qPCR in duplicates). (E-H) Effect of Senexin B on HCT116 hepatic metastasis. Vehicle or Senexin B (oral b.i.d., 5 days a week) (n=9) were administered for 6 weeks. E: Representative images of HCT116 tumor-bearing livers in mice treated with Senexin B or vehicle control. F: Weights of tumor-bearing livers. G: Representative H&E staining of hepatic metastases. T: tumor. Scale bars: 1 mm. H: quantitation of relative tumor areas in the liver (n = 4). * denotes P<0.05, ** denotes P<0.01 and *** denotes P<0.001.